Regulatory Watch
June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022

Peptide Partners

peptide.partners ↗
Founded: 2023 HQ: USA Last reviewed: February 20, 2026
B+
Overall Grade
Transparency 80/100
Testing 90/100
Pricing 55/100
Reputation 60/100
Compliance 65/100
Publishes COA Yes
Third-Party Testing Yes
FDA Warning Letters 0
Product Types injectable, lyophilized-powder, research-chemical

Peptide Partners

Overview

Peptide Partners is a relatively new US-based vendor that has rapidly distinguished itself through the most comprehensive independent testing program in the grey-market peptide space. With 40 samples independently tested by Finnrick Analytics across 5 products — and ratings ranging from A to C — the company has deliberately made verifiable quality its primary competitive differentiator.

What We Found

Testing & Quality (Score: 80/100)

Peptide Partners’ testing data is the strongest we’ve evaluated:

  • BPC-157: Finnrick A (“Great”) — top-rated alongside Peptide Sciences and Eternal Peptides
  • Retatrutide: Finnrick A (“Great”) — 13 samples tested (Jul 2025–Jan 2026), most recent data of any vendor
  • 40 total samples tested across 5 products — the largest sample set we’ve seen for a single vendor

Critically, Peptide Partners has elected to have all samples tested against label claims rather than using inflated “batch claims” — a more conservative and honest approach. Each vial includes a Batch ID on the label that can be reconciled against COAs for purity, assay, endotoxin, heavy metals, and sterility testing, all publicly accessible at their website.

The label format itself is documented: white BOPP label with logo, molecule identification, weight, batch code, and “Research Use Only” designation. This level of traceability is unusual in the grey market.

Transparency (Score: 75/100)

Among the most transparent vendors we’ve profiled:

  • Public COA archive with batch-specific reports
  • Batch IDs on every vial linking to testing data
  • Purity, assay, endotoxin, heavy metals, and sterility testing documented
  • Testing against label claims (not inflated batch claims)
  • Finnrick partnership for independent verification

The main limitation is relative newness — the company doesn’t have years of operational history to validate consistency over time.

Pricing (Score: 55/100)

Premium pricing reflecting the testing investment. Higher than budget vendors but the testing overhead is a real cost. Free domestic shipping for orders over $400.

Reputation (Score: 55/100)

Limited review history due to relative newness. The Finnrick data serves as the primary trust signal. No significant community controversies or complaints identified, but also no years-long track record of satisfied customers. The Finnrick partnership and testing transparency have generated positive attention in peptide research communities.

Compliance (Score: 60/100)

Standard “Research Use Only” disclaimers. Professional labeling with clear research-only designation. The comprehensive testing program (including endotoxin and sterility) suggests an operational standard above typical grey-market practice. No known regulatory actions.

The PeptideExaminer Verdict

Peptide Partners represents what the grey-market peptide space could look like if testing transparency became the norm rather than the exception. The Finnrick testing program — 40 samples, A ratings on flagship products, testing against label claims rather than batch claims — sets a standard that few competitors match. The premium pricing reflects this investment. The main limitation is newness: we need to see this consistency maintained over years, not months. But on verifiable quality metrics, Peptide Partners currently leads the market.

Grade: B+

CategoryScoreWeightWeighted
Transparency7520%15.0
Testing8025%20.0
Pricing5515%8.25
Reputation5520%11.0
Compliance6020%12.0
Total66.25 → B+

Sources: Finnrick Analytics (finnrick.com, 40 samples), peptide.partners